Advertisement
Advertisement
ACRS
Aclaris Therapeutics, Inc.
4.91
USDSponsored
+0.12
+2.40%
Jun 25, 12:37 UTC -4
Open
ACRS Earnings Reports
Positive Surprise Ratio
ACRS beat 29 of 42 last estimates.
69%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.41M
/-$0.16
Implied change from Q1 26 (Revenue/ EPS)
-29.33%
/+6.67%
Implied change from Q2 25 (Revenue/ EPS)
-20.62%
/+23.08%
Aclaris Therapeutics, Inc. earnings per share and revenue
On May 07, 2026, ACRS reported earnings of -0.15 USD per share (EPS) for Q1 26, beating the estimate of -0.16 USD, resulting in a 6.77% surprise. Revenue reached 2.00 million, compared to an expected 1.35 million, with a 48.06% difference. The market reacted with a +1.67% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 1.41 million USD, implying an increase of 6.67% EPS, and decrease of -29.33% in Revenue from the last quarter.
FAQ
What were Aclaris Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Aclaris Therapeutics, Inc. reported EPS of -$0.15, beating estimates by 6.77%, and revenue of $2.00M, 48.06% above expectations.
How did the market react to Aclaris Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved up 1.67%, changed from $4.78 before the earnings release to $4.86 the day after.
When is Aclaris Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Aclaris Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Aclaris Therapeutics, Inc. is expected to report EPS of -$0.16 and revenue of $1.41M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement